Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer

被引：0

作者：

Hatoum, Hind T. ^{[1
]}

Crawford, E. David ^{[2
]}

Nielsen, Sandy Kildegaard ^{[3
]}

Lin, Swu-Jane ^{[4
]}

Marshall, Dennis C. ^{[5
]}

机构：

[1] Hind T Hatoum & Co, Chicago, IL 60601 USA

[2] Univ Colorado, Aurora, CO 80045 USA

[3] European Mkt Access Ferring Int Ctr SA, CH-1162 St Prex, Switzerland

[4] Univ Illinois, Coll Pharm, Adjunct Fac, Dept Pharm Adm, Chicago, IL 60612 USA

[5] Ferring Pharmaceut Inc, Med Affairs, Parsippany, NJ 07054 USA

来源：

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH | 2013年 / 13卷 / 02期

关键词：

androgen deprivation therapy; cost-effectiveness; degarelix; Markov simulation models; prostate cancer; quality-adjusted life years; COST-EFFECTIVENESS ANALYSIS; COMBINED ANDROGEN BLOCKADE; DRUG COVERAGE DECISIONS; REPORTED OUTCOMES; END-POINT; PERSPECTIVE; HEALTH; IMPLEMENTATION; BICALUTAMIDE; RADIOTHERAPY;

D O I：

10.1586/ERP.13.12

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Androgen deprivation therapy (ADT) is used as first-line therapy for locally advanced or metastatic prostate cancer aiming to reduce testosterone to castrate levels. The authors present an overview of the existing cost-effectiveness studies of ADT in prostate cancer. Cost-effectiveness of ADT was reviewed using a systematic search of the peer-reviewed literature, as well as research abstracts presented at various scientific and industry meetings. Most cost-effectiveness analyses of ADT reported results within the accepted societal threshold of US$50,000 cost/quality-adjusted life year needed to adopt new technology.

引用

页码：251 / 259

页数：9

共 50 条

[31] Low-dose-rate brachytherapy as a primary treatment for localised and locally advanced prostate cancer: a systematic review of economic evaluations
Stanberry, Benedict
Webber-Jones, Nikki
[J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2024,
[32] Hormone therapy for locally advanced prostate cancer
Fowler, JE
Bigler, SA
White, PC
Duncan, WL
[J]. JOURNAL OF UROLOGY, 2002, 168 (02): : 546 - 549
[33] Multimodal therapy of locally advanced prostate cancer
Heidenreich, A.
Boehmer, D.
[J]. UROLOGE, 2016, 55 (03): : 333 - 344
[34] Radiation therapy of locally advanced prostate cancer
Schmidt-Hegemann, N. -S.
Li, M.
Eze, C.
Belka, C.
Ganswindt, U.
[J]. UROLOGE, 2017, 56 (11): : 1402 - 1409
[35] Is adjuvant hormonal therapy necessary to Japanese patients with locally advanced prostate cancer treated by 3D-CRT?
Sakamoto, M.
Mizowaki, T.
Mitsumori, M.
Takayama, K.
Sasai, K.
Negoro, Y.
Norihisa, Y.
Kamoto, T.
Ogawa, O.
Hiraoka, M.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S339 - S339
[36] PREOPERATIVE ENDOCRINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED PROSTATE-CANCER
MAEDA, O
MEGURO, N
SAIKI, S
KINOUCHI, T
KURODA, M
USAMI, M
KOTAKE, T
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1995, 25 (04) : 135 - 139
[37] Adjuvant therapy improves survival in patients with locally advanced prostate cancer
不详
[J]. ONCOLOGY-NEW YORK, 2000, 14 (04): : 479 - 479
[38] Recent progress in hormonal therapy for advanced prostate cancer
Daskivich, Timothy J.
Oh, William K.
[J]. CURRENT OPINION IN UROLOGY, 2006, 16 (03) : 173 - 178
[39] THE ANALYSIS OF THE EFFECT OF HORMONAL THERAPY FOR ADVANCED METASTATIC PROSTATE CANCER IN CHINESE PATIENTS
Ma, Chunguang
Ye, Dingwei
[J]. JOURNAL OF UROLOGY, 2010, 183 (04): : E261 - E261
[40] Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer - Discussion
Pavone-Macaluso
Bolla, M
Zerbib, M
[J]. EUROPEAN UROLOGY, 1999, 35 : 26 - 26

← 1 2 3 4 5 →